CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

CAR-T Therapies (Kymriah®, Yescarta®, Abecma®) – for hematological malignancies like B-cell lymphoma and multiple myeloma Hemgenix® (CSL Behring) – the first gene therapy for Hemophilia B Each of ...

Abecma is a prescription drug used to treat multiple myeloma. Find out about possible interactions with alcohol, other drugs, supplements, foods, and… READ MORE ...

Poolbeg Pharma plc Poolbeg granted FDA Orphan Drug Designation for POLB 001 27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company ...

Average rate from Summary of Product Characteristics (SmPCs) for Yescarta, Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly, Tecvayli and Talvey This announcement was deemed ...

Targeted Oncology TM: What led to the approval of idecabtagene vicleucel (ide-cel; Abecma) after 2 prior lines of therapy for multiple myeloma? Samuel M. Rubinstein, MD, MSCI: The trial supporting ide ...